SARS-CoV Matrix Antibody is affinity chromatography purified via peptide column.
免疫原
Anti-SARS-CoV Matrix antibody was raised against a peptide corresponding to 13 amino acids near the amino-terminus of SARS-CoV Matrix protein. The immunogen is located within the first 50 amino acids of SARS-CoV Matrix.
SARS-CoV Matrix antibody can be used for the detection of SARS-CoV Matrix protein in ELISA. It will detect 5 ng of free peptide at 1 μ,g/mL.
限制
仅限研究用
状态
Liquid
浓度
1 mg/mL
缓冲液
SARS-CoV Matrix Antibody is supplied in PBS containing 0.02 % sodium azide.
储存液
Sodium azide
注意事项
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
-20 °C,4 °C
储存方法
SARS-CoV Matrix antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
M protein antibody, matrix protein antibody, M antibody
物质类
Viral Protein
背景
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019-20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4).